glp-1 ckd agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity Glucagon-Like Peptide-1 Receptor Agonist Use
Description
M., Wahlund, P
doi:10.1038/s41467-024-51076-4 25
Addiction (Abingdon, England) , 120 (2), 236250
The newer GLP-1 pills are taken once daily
The region is witnessing rapid clinical adoption supported by local pharmaceutical innovation, growing endocrinology services, and increasing investment in biopharmaceutical production
& Razvi, S
